No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Protalix Biotherapeutics Gains Momentum in the Rare Disease Space: Analysts | NYSE-A:PLX
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics Analyst Ratings
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Raises Target Price to $15
Protalix BioTherapeutics Outlines Strategic Roadmap for 2025 | NYSE:PLX
NYSE American New 52-Week Highs And Lows